X0306 4 2021-05-04 1 0001785530 Werewolf Therapeutics, Inc. HOWL 0001858705 Arkin Bio Ventures 2 L.P. 6 HACHOSHLIM STREET HERZLIYA PITUACH L3 4672406 ISRAEL 0 0 1 0 0001858707 Arkin Bio Ventures GPGP Ltd. 6 HACHOSHLIM STREET BUILDING C HERZLIYA PITUACH L3 4672406 ISRAEL 0 0 1 0 0001321178 Arkin Moshe 6 HACHOSHLIM ST. HERZELIA L3 4672406 ISRAEL 0 0 1 0 Common Stock 2021-05-04 4 C 0 1235917 A 1235917 I See footnote Common Stock 2021-05-04 4 C 0 410717 A 1646634 I See footnote Common Stock 2021-05-04 4 P 0 400000 16.00 A 2046634 I See footnote Series A Preferred Stock 2021-05-04 4 C 0 10714284 0.00 D Common Stock 1235917 0 I See footnote Series B Preferred Stock 2021-05-04 4 C 0 3560551 0.00 D Common Stock 410717 0 I See footnote On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. This Form 4 shall not be construed as an admission by any of the Reporting Persons or any other entity named in this Form 4 that it is the beneficial owner of any of the securities covered by this Form 4, and each such Reporting Person or entity disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein. Arkin Bio Ventures 2 L.P., By: Its ultimate General Partner, Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04 Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04 Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact 2021-05-04